During the past years, several new classes of inhibitors against EGFR have been developed and have shown promising effects in targeting metastasized cancers of the lung, breast, colorectal system, and head and neck (Bertotti et al. 2015; Blaszczak et al. 2017; Chong and Jänne 2013; Munagala et al. 2011). This evidence concerns the gene EGFR and cancer.